钇-90放射栓塞治疗脑肿瘤:犬模型概念验证与安全性分析
研究在3只健康犬和5只自发性脑内肿块患犬中评估90Y玻璃微球脑动脉放射栓塞的安全性、可行性和初步疗效。健康犬平均吸收剂量为14.0、30.9和73.2 Gy,患犬肿块剂量为45.5-64.1 Gy,未受累脑组织为15.4-33.3 Gy。6只动物出现短暂急性神经功能缺损,7-33天恢复,患犬肿块体积缩小24-94%,部分缓解。
要点
- 90Y玻璃微球经脑动脉放射栓塞在犬模型中技术可行。
- 健康犬治疗组织平均吸收剂量14.0-73.2 Gy,最大剂量超1000 Gy,未見皮质萎缩。
- 患犬肿块吸收剂量45.5-64.1 Gy,1个月时肿块体积缩小24-94%。
核心结论
- 90Y放射栓塞在犬模型中技术可行且安全性可接受。
- 初步疗效数据显示对脑肿瘤有 encouraging 的治疗潜力。
研究设计与样本
- 研究纳入3只健康研究犬(R1-R3)和5只自发性脑内肿块患犬(P1-P5)。
- 研究犬经单侧颈内动脉、大脑中动脉和大脑后动脉行90Y玻璃微球放射栓塞,患犬经颈内动脉治疗。
- 治疗后行90Y PET/CT和系列神经学检查,研究犬1个月后安乐死行微剂量学和病理分析,患犬行1、3、6个月MRI随访。
主要发现
- 研究犬R1-R3治疗组织平均吸收剂量分别为14.0、30.9和73.2 Gy,最大剂量超过1000 Gy。
- 研究犬病理分析未见皮质萎缩,仅见直径小于2 mm的慢性梗死灶。
- 患犬P1-P5肿块吸收剂量分别为45.5、57.6、58.1、45.4和64.1 Gy,未受累脑组织剂量分别为15.4、27.6、19.2、16.7和33.3 Gy。
- 6只动物出现急性神经功能缺损,所有存活犬在治疗后7至33天恢复。
- 患犬1个月时肿块体积缩小24-94%,P1、P3和P4在6个月时达部分缓解,P2在5个月时肿块进展超过治疗前大小并被安乐死。
临床怎么用
- 90Y放射栓塞可作为脑肿瘤的微创治疗候选方案,但需密切监测短暂神经功能缺损。
局限性
- 研究为犬模型概念验证,样本量小,结论需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety, feasibility, and preliminary efficacy of yttrium-90 (90Y) radioembolization (RE) as a minimally invasive treatment in a canine model with presumed spontaneous brain cancers. MATERIALS: Three healthy research dogs (R1-R3) and five patient dogs with spontaneous intra-axial brain masses (P1-P5) underwent cerebral artery RE with 90Y glass microspheres (TheraSphere). 90Y-RE was performed on research dogs from the unilateral internal carotid artery (ICA), middle cerebral artery (MCA), and posterior cerebral artery (PCA) while animals with brain masses were treated from the ICA. Post-treatment 90Y PET/CT was performed along with serial neurological exams by a veterinary neurologist. One month after treatment, research dogs were euthanized and the brains were extracted and sent for microdosimetric and histopathologic analyses. Patient dogs received post-treatment MRI at 1-, 3-, and 6-month intervals with long-term veterinary follow-up. RESULTS: The average absorbed dose to treated tissue in R1-R3 was 14.0, 30.9, and 73.2 Gy, respectively, with maximum doses exceeding 1000 Gy. One month after treatment, research dog pathologic analysis revealed no evidence of cortical atrophy and rare foci consistent with chronic infarcts, e.g., < 2-mm diameter. Absorbed doses to masses in P1-P5 were 45.5, 57.6, 58.1, 45.4, and 64.1 Gy while the dose to uninvolved brain tissue was 15.4, 27.6, 19.2, 16.7, and 33.3 G, respectively. Among both research and patient animals, 6 developed acute neurologic deficits following treatment. However, in all surviving dogs, the deficits were transient resolving between 7 and 33 days post-therapy. At 1 month post-therapy, patient animals showed a 24-94% reduction in mass volume with partial response in P1, P3, and P4 at 6 months post-treatment. While P2 initially showed a response, by 5 months, the mass had advanced beyond pre-treatment size, and the dog was euthanized. CONCLUSION: This proof of concept demonstrates the technical feasibility and safety of 90Y-RE in dogs, while preliminary, initial data on the efficacy of 90Y-RE as a potential treatment for brain cancer is encouraging.
引用
- Pasciak AS, Manupipatpong S, Hui FK, et al. Yttrium-90 radioembolization as a possible new treatment for brain cancer: proof of concept and safety analysis in a canine model. EJNMMI Res. 2020. PMID: 32804262. doi:10.1186/s13550-020-00679-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。